Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Margaret von Mehren(Temple University Health System), Mary Anne Bergman(National Comprehensive Cancer Network)

Journal of the National Comprehensive Cancer Network

July 1, 2022

10.6004/jnccn.2022.0035

Cited by 1,141

Related Papers

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

|The Lancet|2012|1.4k

NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors

|Journal of the National Comprehensive Cancer Network|2010|1.2k

Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

|Journal of the National Comprehensive Cancer Network|2018|733

NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines

|Journal of the National Comprehensive Cancer Network|2007|636

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665

|Journal of Surgical Oncology|2008|419